Vistagen Therapeutics, Inc. (VTGN) — SEC Filings
Vistagen Therapeutics, Inc. (VTGN) — 40 SEC filings. Latest: 8-K (Dec 22, 2025). Includes 25 8-K, 5 SC 13G/A, 4 10-Q.
View Vistagen Therapeutics, Inc. on SEC EDGAR
Overview
Vistagen Therapeutics, Inc. (VTGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 3, 2025: Vistagen Therapeutics, Inc. filed an 8-K on December 3, 2025, reporting events as of November 28, 2025. The filing includes information regarding the departure and election of directors, appointment of officers, and compensatory arrangements. It also covers Regulation FD disclosures and financial st
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 37 neutral. The dominant filing sentiment for Vistagen Therapeutics, Inc. is neutral.
Filing Type Overview
Vistagen Therapeutics, Inc. (VTGN) has filed 25 8-K, 4 10-Q, 3 DEF 14A, 2 10-K, 5 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of VTGN's 27 recent filings, 3 were flagged as high-risk, 8 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
Key Executives
- Shawn K. Singh, J.D.
- Margaret FitzPatrick
Industry Context
Vistagen Therapeutics operates in the highly competitive pharmaceutical sector, focusing on novel treatments for neurological and psychiatric disorders. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success often depends on innovation, clinical trial efficacy, and securing substantial funding.
Top Tags
filing (9) · corporate-governance (7) · 8-k (6) · 8-K (5) · financials (4) · financial-reporting (3) · regulatory-filing (3) · leadership-change (2) · Biotechnology (2) · Pharmaceuticals (2)
Executive Compensation
From the most recent DEF 14A filing (Jul 28, 2025):
- Not Disclosed — Principal Executive Officer: $0
- Not Disclosed — Principal Financial Officer: $0
- Not Disclosed — Principal Accounting Officer: $0
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Sublicense and Other Revenue | $0 | for the three months ended June 30, 2025, indicating no operational income. |
| Period End Date | 2024-12-31 | The 10-Q covers financial information up to this date. |
| Filing Date | 2025-02-13 | The date the report was officially submitted to the SEC. |
| Accession Number | 0001411685-25-000007 | Unique identifier for the filing |
| SEC File Number | 001-37761 | Company's SEC file number |
| Revenue (Q2 FY24) | $0.00 | No revenue generated in the second quarter of fiscal year 2024. |
| Revenue (H1 FY24) | $0.00 | No revenue generated in the first half of fiscal year 2024. |
| Commission File Number | 000-54014 | Identifies the company's SEC filing history. |
| IRS Employer Identification Number | 20-5093315 | Company's tax identification number. |
| Fiscal Year End | 2024-03-31 | The period covered by the compensation details in the filing. |
| Start of Fiscal Year | 2023-04-01 | The beginning of the reporting period for executive compensation. |
| Private Placement Proceeds | $100.0M | Gross proceeds to fund general corporate purposes, clinical pipeline advancement, and commercialization efforts. |
| Fiscal Year Start | 2023-04-01 | The beginning of the reporting period. |
| Prior Fiscal Year Start | 2022-04-01 | The beginning of the prior reporting period. |
| Special Meeting Date | May 29, 2024 | Date of the virtual special meeting of stockholders. |
Frequently Asked Questions
What are the latest SEC filings for Vistagen Therapeutics, Inc. (VTGN)?
Vistagen Therapeutics, Inc. has 40 recent SEC filings from Jan 2024 to Dec 2025, including 25 8-K, 5 SC 13G/A, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VTGN filings?
Across 40 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 37 neutral. The dominant sentiment is neutral.
Where can I find Vistagen Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vistagen Therapeutics, Inc. (VTGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vistagen Therapeutics, Inc.?
Key financial highlights from Vistagen Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VTGN?
The investment thesis for VTGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vistagen Therapeutics, Inc.?
Key executives identified across Vistagen Therapeutics, Inc.'s filings include Shawn K. Singh, J.D., Margaret FitzPatrick.
What are the main risk factors for Vistagen Therapeutics, Inc. stock?
Of VTGN's 27 assessed filings, 3 were flagged high-risk, 8 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Vistagen Therapeutics, Inc.?
Forward guidance and predictions for Vistagen Therapeutics, Inc. are extracted from SEC filings as they are enriched.